[TAANN] QoQ Annualized Quarter Result on 30-Sep-2021 [#3]

Stock
[TAANN] TA ANN HOLDINGS BHD
Announcement Date
22-Nov-2021
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2021
Quarter
30-Sep-2021 [#3]
Profit Trend
QoQ- 26.49%
YoY- 229.56%
Quarter Report
Latest QR
Upcoming QR
TAANN's Result
TAANN's Financial Summary
View:
Show?
Annualized Quarter Result
30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 CAGR
Revenue 2,283,814 1,951,016 1,894,353 1,710,429 1,591,930 1,362,484 1,217,759 52.25%
PBT 580,550 459,276 465,389 369,994 303,006 190,248 134,454 165.87%
Tax -110,100 25,260 -72,997 -17,730 -26,540 1,084 -57,979 53.52%
NP 470,450 484,536 392,392 352,264 276,466 191,332 76,475 236.85%
-
NP to SH 393,278 418,480 314,422 291,206 230,224 163,900 45,090 325.40%
-
Tax Rate 18.96% -5.50% 15.69% 4.79% 8.76% -0.57% 43.12% -
Total Cost 1,813,364 1,466,480 1,501,961 1,358,165 1,315,464 1,171,152 1,141,284 36.27%
-
Net Worth 1,726,611 1,682,564 1,594,472 1,581,258 1,523,998 1,449,119 1,431,501 13.34%
Dividend
30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 CAGR
Div 264,277 264,277 132,138 176,184 - - 66,069 152.62%
Div Payout % 67.20% 63.15% 42.03% 60.50% - - 146.53% -
Equity
30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 CAGR
Net Worth 1,726,611 1,682,564 1,594,472 1,581,258 1,523,998 1,449,119 1,431,501 13.34%
NOSH 444,645 444,645 444,645 444,645 444,645 444,645 444,645 0.00%
Ratio Analysis
30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 CAGR
NP Margin 20.60% 24.84% 20.71% 20.60% 17.37% 14.04% 6.28% -
ROE 22.78% 24.87% 19.72% 18.42% 15.11% 11.31% 3.15% -
Per Share
30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 CAGR
RPS 518.50 442.95 430.08 388.33 361.42 309.33 276.47 52.25%
EPS 89.28 95.00 71.38 66.12 52.26 37.20 10.24 325.29%
DPS 60.00 60.00 30.00 40.00 0.00 0.00 15.00 152.62%
NAPS 3.92 3.82 3.62 3.59 3.46 3.29 3.25 13.34%
Adjusted Per Share Value based on latest NOSH - 444,645
30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 CAGR
RPS 518.64 443.06 430.19 388.43 361.52 309.41 276.54 52.25%
EPS 89.31 95.03 71.40 66.13 52.28 37.22 10.24 325.39%
DPS 60.02 60.02 30.01 40.01 0.00 0.00 15.00 152.68%
NAPS 3.921 3.821 3.6209 3.5909 3.4609 3.2908 3.2508 13.34%
Price Multiplier on Financial Quarter End Date
30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 CAGR
Date 30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 -
Price 3.98 5.15 3.51 2.94 2.54 2.85 3.03 -
P/RPS 0.77 1.16 0.82 0.76 0.70 0.92 1.10 -21.21%
P/EPS 4.46 5.42 4.92 4.45 4.86 7.66 29.60 -71.78%
EY 22.43 18.45 20.34 22.49 20.58 13.06 3.38 254.36%
DY 15.08 11.65 8.55 13.61 0.00 0.00 4.95 110.57%
P/NAPS 1.02 1.35 0.97 0.82 0.73 0.87 0.93 6.36%
Price Multiplier on Announcement Date
30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 CAGR
Date 29/08/22 23/05/22 28/02/22 22/11/21 30/08/21 25/05/21 23/03/21 -
Price 3.97 5.60 5.49 3.21 2.76 2.87 2.88 -
P/RPS 0.77 1.26 1.28 0.83 0.76 0.93 1.04 -18.20%
P/EPS 4.45 5.89 7.69 4.86 5.28 7.71 28.13 -70.84%
EY 22.49 16.97 13.00 20.60 18.94 12.97 3.55 243.53%
DY 15.11 10.71 5.46 12.46 0.00 0.00 5.21 103.76%
P/NAPS 1.01 1.47 1.52 0.89 0.80 0.87 0.89 8.82%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment